Clinical Trial

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-04-30; most recent amendment 2025-12-05.
Status change: Not Yet Recruiting → Recruiting 2020-09-15
Trial Details
NCT Number NCT03935295
Lead Sponsor Johns Hopkins University
Conditions Adolescent Idiopathic Scoliosis
Enrollment 90 participants
Start Date 2020-09-03
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-09